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antitumor activity, and pharmacokinetics of LJM716 in 
Japanese patients.
Methods LJM716 was administered intravenously at doses 
of 10, 20, or 40 mg/kg once weekly, in 28-day cycles, to 
12 patients with HER2-amplified breast cancer or gastric 
cancer, or with esophageal squamous cell carcinoma or 
squamous cell carcinoma of the head and neck, regardless 
of HER2 status.
Results The maximum tolerated dose was not reached, 
and the recommended dose was established at 40 mg/
kg. No dose-limiting toxicities were observed in the first 
cycle. The most frequently reported adverse events were 
diarrhea, fatigue, stomatitis, pyrexia, and paronychia. One 
unconfirmed partial response was observed in a patient 
with breast cancer, and 50% of the patients achieved sta-
ble disease as the best overall response. Exposure increased 
with ascending dose, and half-life was estimated to be 
11–14 days. No anti-LJM716 antibodies were detected.
Conclusions LJM716 was well tolerated in Japanese 
patients, and a degree of tumor shrinkage was observed.
Clinical trial information ClinicalTrials.gov 
NCT01911936.
Keywords HER3 · HER2 · LJM716 · Monoclonal 
antibody · Phase I
Introduction
Inappropriate activation of the human epidermal growth 
factor receptor (HER) family of tyrosine kinases has 
been implicated in a wide variety of different cancers 
[1]. Activation occurs via homo- or heterodimerization of 
HER family members, inducing kinase activity and sub-
sequent downstream activation of intracellular signaling 
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pathways. HER3 lacks significant kinase activity [2] but 
has recently been recognized as an important component 
of receptor tyrosine kinase-driven tumorigenesis, dimer-
izing with and activating other HER family members, 
such as epidermal growth factor receptor (EGFR) and 
HER2 [3]. Overexpression of HER2 or interaction with 
the ligand, neuroregulin1 (NRG1), promotes HER2:HER3 
heterodimerization and subsequent phosphoinositide 
3-kinase signaling, driving tumor cell proliferation and 
tumor growth [1, 3]. HER3 therefore plays an important 
role in the development and maintenance of HER2- and 
NRG1-driven cancers, and represents an attractive target 
for directed therapy.
The efficacy of HER2-directed therapies has already 
been demonstrated, and approved drugs include the mon-
oclonal antibodies, trastuzumab and pertuzumab, and the 
tyrosine kinase inhibitor, lapatinib [4–6]. Although the use 
of these drugs has vastly improved the treatment options 
for patients with HER2-driven cancer, problems with 
resistance have been documented. Resistance can develop 
through multiple mechanisms, including cross-activation 
by and compensatory upregulation of other HER fam-
ily members, including HER3 [7]. As such, targeting 
HER2 and HER3 simultaneously is hoped to improve 
response to treatment; indeed, promising outcomes have 
been reported following combination of HER2-directed 
therapies with other therapies [8–10]. A number of can-
cer types are good candidates for HER3-directed therapy. 
Dysregulated HER2 expression has been documented in 
esophageal squamous cell carcinoma (ESCC; 31%) [11], 
metastatic breast cancer (18–20%) [7], and gastric/gas-
troesophageal junction cancer (15–30%) [12]. In addi-
tion to HER2-driven cancers, preclinical data suggest that 
NRG1-driven cancers, which include a significant propor-
tion of squamous cell carcinomas of the head and neck 
(SCCHN), are also likely to benefit from HER3-directed 
therapy [13, 14].
LJM716 is a fully human IgG monoclonal antibody 
that specifically binds HER3, trapping it in the inactive 
conformation. LJM716 is uniquely able to block both the 
ligand-independent and ligand-dependent modes of HER3 
activation, and antitumor activity has been demonstrated 
in both HER2-amplified and NRG1-driven xenograft mod-
els [15, 16]. In a recent global phase I clinical trial in pre-
dominantly Western Caucasian patients with HER2-overex-
pressing breast cancer or gastric cancer, and with ESCC or 
SCCHN, regardless of HER2 status (NCT01598077), sin-
gle-agent LJM716 was well tolerated up to a recommended 
dose (RD) of 40 mg/kg [17]. Here, the safety and tolera-
bility of single-agent LJM716 were evaluated in Japanese 
patients in the same indications.
Materials and methods
Study oversight
This was a phase I, open-label, multicenter study (clinical-
trials.gov registry number NCT01911936) [18]. The accrual 
period, from the first patient visit to the last patient visit, 
was from September 19, 2013, to March 6, 2015. The study 
was designed by the sponsor (Novartis Pharmaceuticals 
Corporation) and performed in accordance with the princi-
ples of Good Clinical Practice. The protocol was approved 
by an Institutional Review Board at each institution, and the 
study was conducted according to the ethical principles of 
the Declaration of Helsinki. All patients provided written 
informed consent before any study procedures.
Patient selection
All patients were aged ≥18 years, had an Eastern Coop-
erative Oncology Group (ECOG) performance status of 
≤2, and had HER2-overexpressing or amplified (HER2+) 
locally advanced/metastatic breast cancer or gastric cancer, 
or recurrent or metastatic SCCHN or ESCC, regardless of 
HER2 status, for which no effective treatment option exists 
(investigator decision). For breast cancer, patients were 
required to have tumors with 3+ HER2-overexpression 
documented by immunohistochemistry or amplification by 
in situ hybridization; for gastric cancer (including gastroe-
sophageal junction tumors), patients were required to have 
tumors with immunohistochemistry 2+ or 3+ and ampli-
fication by in situ hybridization [19, 20]. Exclusion crite-
ria included patients with untreated or symptomatic central 
nervous system metastases, other primary malignancies 
requiring intervention, or prior treatment with an anti-
HER3 antibody.
Study objectives
The primary objectives for the study were to determine the 
maximum tolerated dose (MTD) and/or RD of LJM716 as 
a single agent when administered intravenously (IV) to Jap-
anese patients with advanced solid tumors. The secondary 
objectives were to characterize the safety and tolerability, 
pharmacokinetics (PK), and preliminary antitumor activ-
ity of LJM716, and to assess the emergence of antibodies 
against LJM716.
Study design and treatment plan
During the dose-escalation part, at least 12 patients were 
planned to be treated in successive cohorts. The starting 
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dose was 10 mg/kg LJM716, followed by 20 and 40 mg/kg, 
given by IV infusion over 2 h once weekly (QW) in 28-day 
cycles. An adaptive Bayesian logistic regression model 
(BLRM) [21] incorporating escalation with overdose con-
trol criteria was used to guide dose-escalation decisions 
[22, 23], and provide support to establish the MTD or RD 
for LJM716.
Premedication prior to each dose of LJM716 was recom-
mended (650 mg acetaminophen or equivalent and 50 mg 
IV diphenhydramine or equivalent) to circumvent infusion-
related reactions. Dose reductions to ≥10 mg/kg were 
permitted, as were dose interruptions ≤28 days. LJM716 
administration was discontinued in the event of disease 
progression, unacceptable adverse events (AEs), or as the 
result of patient or physician decision. It was decided not to 
open the dose-expansion part of this study.
Toxicity assessments
Safety assessments were carried out based on all AEs and 
their relationship to the study drug treatment, with regular 
monitoring of hematology, blood chemistry, and urine anal-
ysis, and regular assessment of vital signs, physical condi-
tion, body weight, performance status, and cardiac function. 
AEs were assessed according to the National Cancer Insti-
tute Common Terminology Criteria for Adverse Events, 
version 4.03. Dose-limiting toxicities (DLTs) were defined 
as AEs or abnormal laboratory values assessed as unrelated 
to disease progression, intercurrent illness, or concomitant 
medication, as defined in Supplemental Table 1.
Response assessments
Tumor lesions were assessed by investigators according to 
Response Evaluation Criteria In Solid Tumors (RECIST) 
guidelines, version 1.1 [24]. Patients underwent screen-
ing computed tomography (CT) scans of the chest, abdo-
men, and pelvis, and MRI where evaluation by CT was not 
adequate. Visible skin lesions and easily palpable subcu-
taneous tumors were measured by physical examination. 
Screening was performed within 28 days of the first dose. 
The post-baseline RECIST assessments were performed 
every two cycles and then at the end of treatment if a scan 
was not conducted 30 days prior to this.
Pharmacokinetics and immunogenicity
Serum was collected for PK assessments at multiple time 
points, including serial samplings to calculate PK param-
eters (Cycle 1 and Cycle 3) and trough samplings (Day 
1 of each cycle). The serum concentration of LJM716 
was measured using a validated ELISA. PK param-
eters (maximum observed serum concentration after drug 
administration [Cmax], time to Cmax [Tmax], area under the 
curve [AUC], etc.) were determined by a non-compartmen-
tal method with a lower limit of quantification of 150 ng/




A total of 12 patients were treated with intravenous 
LJM716 at doses of 10, 20, and 40 mg/kg QW, between 
September 19, 2013, and March 6, 2015. The median 
age of patients was 58 years (range, 33‒75); 8/12 (67%) 
patients were aged <65 years; 6/12 (50%) were male; 4/12 
(33%) had an ECOG performance status of 1; and 1/12 
(8%) had an ECOG performance status of 2. Confirmed 
primary tumor types at enrollment were ESCC [n = 2 
(17%)], SCCHN [n = 2 (17%)], HER2-overexpressing 
breast cancer [n = 6 (50%)], and HER2-overexpressing 
gastric cancer [n = 2 (17%)]. All patients had stage IV dis-
ease at study entry. All patients had received prior antineo-
plastic therapies (median 6; range, 2–13), including trastu-
zumab in eight patients. Patient demographics are given in 
Table 1. The median duration of exposure was 14.0 weeks 
(range, 4.0–48.1) across all LJM716 doses, and most 
patients (92%) had an exposure of >4 weeks (Supplemental 
Table 2). All 12 patients discontinued treatment due to dis-
ease progression.
Toxicity
No DLTs were reported in the first cycle of the study. Grade 
3 pneumonia aspiration observed in one patient (40 mg/kg) 
during Cycle 2 met the DLT criteria as described in Supple-
mental Table 1 (other ≥grade 3 non-hematologic toxicity). 
The MTD was not reached, and the RD was established 
at 40 mg/kg QW based on the BLRM, safety, tolerability, 
and PK data. All patients had at least one AE, regardless 
of study drug relationship. The most frequent AEs in all 
patients were diarrhea (50%), stomatitis (42%), fatigue, 
edema peripheral, and pyrexia (33% each). There were 
no clinically relevant differences in AEs across the study 
groups. At the RD of 40 mg/kg, the most frequent AEs 
were diarrhea, pyrexia (50% each), fatigue, nasopharyngi-
tis, anemia, and lymphocyte count decreased (33% each; 
Table 2). AEs assessed as infusion-related reactions were 
only observed in the 40 mg/kg dose group (pyrexia in three 
patients and headache in one patient). Five grade 3/4 AEs 
were reported: pneumonia aspiration, anemia, neutrope-
nia, hyponatremia, and hypophosphatemia in one patient 
(8%) each, and decreased lymphocyte count in two patients 
134 Cancer Chemother Pharmacol (2017) 79:131–138
1 3
Table 1  Patient demographics 
and disease characteristics, by 
treatment group









Age, years (median) 69.0 58.0 51.5 58.0
 <65, n (%) 1 (33) 2 (67) 5 (83) 8 (67)
 ≥65, n (%) 2 (67) 1 (33) 1 (17) 4 (33)
Sex, n (%)
 Female 2 (67) 1 (33) 3 (50) 6 (50)
 Male 1 (33) 2 (67) 3 (50) 6 (50)
ECOG PS, n (%)
 0 1 (33) 1 (33) 5 (83) 7 (58)
 1 2 (67) 2 (67) 0 4 (33)
 2 0 0 1 (17) 1 (8)
Primary site of cancer, n (%)
 Breast 2 (67) 1 (33) 3 (50) 6 (50)
 Esophagus 0 0 2 (33) 2 (17)
 Head and neck 0 1 (33) 1 (17) 2 (17)
 Gastric 1 (33) 1 (33) 0 2 (17)
Primary tumor histology, n (%)
 Squamous cell carcinoma 0 1 (33) 3 (50) 4 (33)
 Adenocarcinoma 3 (100) 2 (67) 3 (50) 8 (67)
Stage at study entry, n (%)
 IV 2 (67) 2 (67) 5 (83) 9 (75)
 IVB 1 (33) 1 (33) 1 (17) 3 (25)
Table 2  Adverse events 
(≥10%), regardless of study 
drug relationship, by treatment 
group
QW once weekly








Diarrhea 2 (67) 1 (33) 3 (50) 6 (50)
Stomatitis 3 (100) 1 (33) 1 (17) 5 (42)
Fatigue 1 (33) 1 (33) 2 (33) 4 (33)
Edema peripheral 1 (33) 2 (67) 1 (17) 4 (33)
Pyrexia 0 1 (33) 3 (50) 4 (33)
Nausea 1 (33) 1 (33) 1 (17) 3 (25)
Cough 2 (67) 0 1 (17) 3 (25)
Pruritus 1 (33) 1 (33) 1 (17) 3 (25)
Nasopharyngitis 0 1 (33) 2 (33) 3 (25)
Paronychia 2 (67) 0 1 (17) 3 (25)
Anemia 0 1 (33) 2 (33) 3 (25)
Decreased appetite 1 (33) 1 (33) 1 (17) 3 (25)
Dysphagia 0 1 (33) 1 (17) 2 (17)
Vomiting 1 (33) 1 (33) 0 2 (17)
Dyspnea 0 1 (33) 1 (17) 2 (17)
Rash 1 (33) 0 1 (17) 2 (17)
Headache 1 (33) 0 1 (17) 2 (17)
Peripheral sensory neuropathy 0 1 (33) 1 (17) 2 (17)
Lymphocyte count decreased 0 0 2 (33) 2 (17)
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(17%). Ten patients (83%) had AEs suspected to be study 
drug-related, and the most common was diarrhea (50%; 
Supplemental Table 3). Two patients (17%) experienced 
grade 3/4 AEs suspected to be study drug-related: pneu-
monia aspiration and neutropenia in one patient (8%) each, 
and decreased lymphocyte count in two patients (17%). 
Two patients reported serious AEs: nausea and vomiting, 
and pneumonia aspiration in one patient (8%) each, of 
which only pneumonia aspiration was suspected to be study 
drug-related. No deaths were reported during the study. No 
AEs that led to study drug discontinuation were reported, 
and four patients (33%) reported AEs requiring dose inter-
ruption: influenza, atrial fibrillation, neutropenia, nasophar-
yngitis, and pneumonia aspiration in one patient each. No 
AEs leading to dose reduction were reported.
Efficacy
Of all treated patients, six (50%) achieved stable disease 
and six (50%) had progressive disease (Table 3). None of 
the patients achieved complete or partial response; how-
ever, 4/6 patients with HER2+ breast cancer showed some 
tumor shrinkage (Fig. 1). One patient with HER2+ breast 
cancer (40 mg/kg) had an unconfirmed partial response 
(tumor shrinkage of more than 30% in Cycle 10), followed 
by subsequent progressive disease.
Pharmacokinetic studies and immunogenicity
The PK parameters for Cycle 1 and Cycle 3 are given in 
Table 4, and these were comparable to those seen previ-
ously in a global study in predominantly Western Cauca-
sian patients [17]. The exposure of LJM716 increased as 
the dose increased. Upon a power model analysis of the 
dose–exposure relationship for AUC from time zero to the 
time of the last quantifiable concentration (AUC0–last) and 
Cmax in Cycle 1, dose-proportionality in the dose range 
Table 3  Best overall response 
in all disease types (investigator 
assessed)
Data cut off: March 6, 2015
CR complete response, PR partial response, QW once weekly








Complete response 0 0 0 0
Partial response 0 0 0 0
Stable disease 3 (100) 1 (33) 2 (33) 6 (50)
 Unconfirmed CR/PR 0 0 1 (17) 1 (8)
Progressive disease 0 2 (67) 4 (67) 6 (50)
Unknown 0 0 0 0
10 mg/kg QW 
20 mg/kg QW 
40 mg/kg QW 































Fig. 1  Best percentage change from baseline in target lesions by 
treatment group. BC breast cancer, ESCC esophageal squamous cell 
carcinoma, GC gastric cancer, QW once weekly, SCCHN squamous 
cell carcinoma of the head and neck. aThe number of patients was 11 
because one patient with ESCC did not have target lesions
Table 4  Pharmacokinetic parameters for LJM716 (Cycle 1; Cycle 3)
AUC0–last area under the curve from time zero to the time of the last 
quantifiable concentration, Cmax maximum observed serum concen-
tration after drug administration, Cmin minimum drug serum concen-
tration, SD standard deviation, Tmax time to reach Cmax













































185; 280 268; 615 9.50; 9.53
40 mg/kg
(n = 1)
243,000 1210 2130 4.73
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10–40 mg/kg was suggested with slope estimates of 0.82 
(90% confidence interval [CI] 0.53–1.12) and 0.85 (90% CI 
0.65–1.04), respectively, near to unity. There was 2.8–3.4-
fold accumulation at steady state in Cycle 3 after repeated 
weekly doses, based on AUC after the first doses of Cycles 
1 and 3. The effective half-life of LJM716 was estimated 
to be 11–14 days, based on the accumulation. All patients 
were tested for antidrug antibodies against LJM716, but 
antibodies were not detected in any of the samples.
Discussion
This study evaluated the safety and tolerability of IV-
administered LJM716 in Japanese patients with solid 
tumors. The RD of LJM716 was established at 40 mg/kg 
QW; the same as that determined in a global clinical trial 
in Western Caucasian patients [17]. The MTD was not 
reached during the course of this study. LJM716 was well 
tolerated with a manageable safety profile, with observed 
toxicities largely grade 1 or 2. The most frequently 
observed AE was diarrhea, which is seen with most other 
HER family inhibitors [25–27]. Diarrhea in this study was 
mild. Similarly, skin toxicities were generally less frequent 
and milder than seen with other HER family inhibitors [6, 
28]. The fact that these toxicities were mild (grade 1 or 2) 
might be considered to be due to the specificity of LJM716 
for HER3; more severe AEs could be expected to result 
from off-target effects. Similarly, more severe AEs are seen 
in combination studies, with grade 3 gastrointestinal prob-
lems and skin toxicities being reported in trials combining 
HER2 or HER3-targeted mAbs with EGFR inhibitors [29–
34]. Of 12 patients treated with LJM716, only one serious 
AE suspected to be drug induced was reported. This was 
aspiration-induced pneumonia in a patient with SCCHN. 
While the cause for this is unknown, serious bacterial pneu-
monia has been reported in two other studies with HER3 
mAbs [27, 33]. Overall, LJM716 was found to have a 
favorable safety profile.
LJM716 demonstrated dose-dependent exposure, with 
an estimated half-life of 11–14 days, and PK parameters 
similar to those observed in the global study and in line 
with other therapeutic antibodies. The AUC/Cmax observed 
at the RD was sufficient to achieve effective systemic drug 
levels, based on preclinical studies. In the preclinical study, 
1–10 nM LJM716 suppressed growth of HER2-overex-
pressing or NRG-stimulated cell lines [15]. In this study, 
the mean Cmax was 243 μg/mL (equivalent to ~1–2 μM 
based on a typical molecular weight of ~150 kDa for a 
human IgG mAb) for the 40 mg/kg dose group at Cycle 1, 
and significantly higher at Cycle 3.
Although no confirmed complete or partial responses 
were observed during the course of the study, tumor 
shrinkage of more than 30% (unconfirmed partial response) 
was observed in one patient with HER2+ breast cancer 
(40 mg/kg group), and tumor shrinkage was also observed 
in three of the other five patients with HER2+ breast can-
cer across all doses. A total of 50% of the patients achieved 
stable disease. Five of the six patients with HER2+ breast 
cancer showing stable disease or an unconfirmed partial 
response had documented progression with the most recent 
prior regimen, which contained trastuzumab, and the sixth 
patient received trastuzumab as part of the second most 
recent treatment regimen. Further investigation is needed to 
confirm whether LJM716 will be an efficacious treatment 
option for patients with breast cancer who are trastuzumab 
resistant.
Future development of HER3-directed therapies may 
benefit from the consideration of appropriate biomarkers. 
NRG1 has been validated as a predictive biomarker for 
response to the HER3-directed mAbs AV-203 and patritu-
mab in preclinical and in clinical studies, respectively [35, 
36]. In contrast, no correlation was seen between tumor 
inhibition and HER3 levels [35].
Although the single-agent LJM716 antitumor activ-
ity observed here was less extensive than that observed 
in preclinical xenograft studies, these same studies estab-
lished that efficacy was significantly improved by combi-
nation of LJM716 with other HER2-directed therapies [15, 
16]. Consistent with this, there is an increasing body of 
clinical evidence demonstrating that the efficacy of HER2/
HER3-directed therapies is improved by combination with 
other anti-HER antibodies [9, 37], tyrosine kinase inhibi-
tors [33, 34], and/or chemotherapy [8, 10]. For example, in 
a phase II trial in which 100% of the patients progressed 
on pertuzumab single-agent therapy, a clinical benefit rate 
(stable disease + partial response + complete response 
≥6 months) of 41% was achieved following subsequent 
combination therapy with trastuzumab [37]. It is notewor-
thy that the addition of LJM716 to trastuzumab resulted in 
increased inhibition of pAKT and improved in vitro effi-
cacy exceeding that achieved by the combination of tras-
tuzumab with pertuzumab [15]. Based on these observa-
tions, the future development of LJM716 is likely to focus 
on combination with other therapies, and a phase I study of 
LJM716 in combination with trastuzumab in patients with 
HER2-overexpressing breast or gastric cancer is currently 
ongoing (NCT01602406).
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